ArticlePloS one2022

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.

Yuichiro Kikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.